Oxford BioDynamics and Agilent Technologies have signed a supply and resale agreement to manufacture and sell the new EpiSwitch Explorer Array Kit. The kit is available for high-resolution 3D genome profiling and biomarker discovery. The EpiSwitch platform has already been used to develop the recently launched Covid-19 Severity Test, EpiSwitch CST.

Abbott has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for the over-the-counter, non-prescription, asymptomatic use of its BinaxNOW COVID-19 Ag Self-Test. The test will be available to individuals with or without symptoms and without a prescription. Abbott is expected to start shipping to major food and drug retailers in the coming weeks.

BioVaxys Technology has applied for pre-IND (Investigational New Drug) meeting request and submitted a briefing package with the FDA for Covid-T, its T-cell immune response diagnostic for SARS-CoV-2. BioVaxys expects a written response to its pre-IND briefing package later this month. Covid-T uses delayed-type hypersensitivity (DTH), a measure of T-cell immunity used for other infectious diseases such as fungal diseases, tuberculosis, and mumps.